News | May 06, 2024
Tatva Chintan Pharma Chem posts Q4 FY24 PAT at Rs. 9.61 Cr
The company has posted net profit of Rs.30.35 crores for the Financial Year ended March 31, 2024
The company has posted net profit of Rs.30.35 crores for the Financial Year ended March 31, 2024
The company has reported total income of Rs. 155.79 crores during the period ended March 31, 2024
The company has reported total income of Rs. 2,943.49 crores during the period ended March 31, 2024
The company has reported total income of Rs. 1,089.58 crores during the period ended March 31, 2024
The company has posted net profit of Rs.87.66 crores for the Financial Year ended March 31, 2024
GAAP net loss of $1.2 billion and GAAP diluted EPS of $(3.07)
TIVDAK is the first antibody-drug conjugate (ADC) to have positive overall survival data for patients with previously treated recurrent or metastatic cervical cancer
First-quarter 2024 revenues totaled $14.9 billion, a decrease of $3.6 billion, or 20%, compared to the prior-year quarter
Philips also concluded an agreement with insurers to pay Philips EUR 540 million to cover Respironics recall-related product liability claims
2024 full-year revenue guidance raised by US$ 2 billion
Subscribe To Our Newsletter & Stay Updated
